| Literature DB >> 34807407 |
Karen Rytter1,2, Kristoffer P Madsen3,4, Henrik U Andersen1, Bryan Cleal3, Eva Hommel1, Mette A Nexø3, Ulrik Pedersen-Bjergaard2,5, Timothy Skinner6, Ingrid Willaing3,7, Kirsten Nørgaard1,2, Signe Schmidt8,9.
Abstract
INTRODUCTION: Insulin pump therapy can improve quality of life and glycaemic outcomes for many people with type 1 diabetes (T1D). The multidimensional Steno Tech Survey study aims to investigate why some insulin pump users do not achieve treatment goals. In this article, we present the study design and analyse differences in population characteristics between responders and non-responders.Entities:
Keywords: HbA1c; Insulin pump; National registries; Response/non-response; Survey; Type 1 diabetes
Year: 2021 PMID: 34807407 PMCID: PMC8607214 DOI: 10.1007/s13300-021-01181-0
Source DB: PubMed Journal: Diabetes Ther ISSN: 1869-6961 Impact factor: 2.945
Fig. 1Flow chart of recruitment procedure. SDCC Steno Diabetes Center Copenhagen, NOH Nordsjællands Hospital Hillerød
Demographic and socioeconomic characteristics overall and by response status
| Variables | Study population ( | Responders ( | Non-responders ( | Missing (responders | non-responders) | |
|---|---|---|---|---|---|
| Age, years | 42 (28–56) | 49 (36–60) | 33 (25–49) | < 0.001 | 1 | 12 |
| Age groups | < 0.001 | ||||
| 18–25 | 277 (18) | 70 (9) | 207 (26) | 1 | 12 | |
| 26–49 | 734 (46) | 320 (42) | 414 (51) | ||
| 50+ | 568 (36) | 379 (49) | 180 (23) | ||
| Sex, female | 909 (58) | 459 (60) | 450 (56) | 0.097 | 1 | 11 |
| Marital status, married | 715 (45) | 439 (57) | 276 (34) | < 0.001 | 1 | 11 |
| Cohabitation | 0.011 | 1 | 11 | |||
| Lives alone | 287 (18) | 135 (18) | 152 (19) | ||
| Lives with at least one other adult | 1192 (76) | 599 (78) | 593 (73) | ||
| Lives only with child(ren) | 100 (6) | 35 (4) | 65 (8) | ||
| Education | < 0.001 | 15 | 44 | |||
| Primary (7th–10th grade) | 166 (11) | 61 (8) | 105 (13) | ||
| High school or vocational school | 670 (44) | 288 (38) | 382 (49) | ||
| Short or medium higher education | 378 (24) | 217 (29) | 161 (21) | ||
| Long higher education | 318 (21) | 189 (25) | 129 (17) | ||
| Employment status, employed | < 0.001 | 1 | 11 | |||
| Employed | 980 (62) | 519 (67) | 461 (57) | ||
| Unemployed | 136 (9) | 52 (7) | 84 (10) | ||
| Retired | 173 (11) | 114 (15) | 59 (7) | ||
| Student | 290 (18) | 84 (11) | 206 (25) | ||
| Yearly disposable personal income, $1000 | 49 (26–71) | 57 (34–78) | 39 (21–63) | < 0.001 | 1 | 12 |
| Yearly disposable family income, $1000 | 73 (43–109) | 80 (48–112) | 68 (39–105) | < 0.001 | 2 | 15 |
Descriptive statistics for categorical data are given as frequencies (%, without missing values) and for continuous data as median (p25–p75). The ‘Not married’ category includes widow/widower, divorced, longest living of two partners and terminated partnership. The “Short- and medium higher education” category includes degrees from business academy and vocational college educations; the “Long higher education” category includes university degrees (bachelor, master and doctorate degrees). The ‘Retired’ category includes both early (e.g., due to disability) and timely (~ 65 years) retirees. Yearly disposable income was converted from Danish Kroner to US dollars using the exchange rate of 1 June 2018 ($1 = DKK6.69); negative income was coded as zero. *P values are for bivariate association tests. Figure 4 depicts adjusted multivariate analysis results
Fig. 4Odds ratios of responding to the questionnaire. Reference categories: age = 18–25 years; sex = male; marital status = unmarried; education = primary school; HbA1c = < 53 mmol/mol; ketoacidosis = no. Only variables containing statistically significant associations are shown. Shown odds ratios are adjusted for one another in the same model together with cohabitation and employment status, income, diabetes duration, neuropathy, cardiovascular disease and Charlson comorbidity index
Clinical characteristics
| Variables | Study population | Responders ( | Non-responders ( | * | Missing (responders | non-responders) |
|---|---|---|---|---|---|
| HbA1c, mmol/mol | 58 (51–65) | 56 (50–62) | 60 (53–69) | < 0.001 | 1 | 8 |
| HbA1c, % | 7.5 (6.8–8.1) | 7.3 (6.7–7.8) | 7.6 (7.0–8.5) | < 0.001 | 1 | 8 |
| HbA1c groups | < 0.001 | 1 | 8 | |||
| < 53 mmol/mol (< 7.0%) | 467 (30) | 264 (34) | 203 (25) | ||
| 53– < 58 mmol/mol (7.0– < 7.5%) | 297 (19) | 167 (22) | 130 (16) | ||
| 58– < 64 mmol/mol (7.5– < 8.0%) | 352 (22) | 177 (23) | 175 (22) | ||
| 64– < 75 mmol/mol (8.0– < 9.0%) | 322 (20) | 134 (17) | 188 (23) | ||
| ≥ 75 mmol/mol (≥ 9%) | 145 (9) | 27 (4) | 118 (15) | ||
| Cholesterol (total), mmol/l | 4.4 (3.9–4.9) | 4.4 (3.9–5) | 4.4 (3.9–4.9) | 0.396 | 43 | 56 |
| HDL, mmol/l | 1.7 (1.4–2.0) | 1.7 (1.4–2.2) | 1.6 (1.4–1.9) | < 0.001 | 43 | 58 |
| LDL, mmol/l | 2.2 (1.8–2.7) | 2.2 (1.7–2.7) | 2.2 (1.8–2.8) | 0.551 | 43 | 58 |
| VLDL, mmol/l | 0.4 (0.3–0.6) | 0.4 (0.3–0.5) | 0.4 (0.3–0.6) | 0.004 | 60 | 81 |
| Triglycerides, mmol/l | 0.8 (0.7–1.2) | 0.8 (0.6–1.2) | 0.9 (0.7–1.3) | 0.001 | 44 | 58 |
| UACR, mg/g | 6 (4–13) | 6 (4–13) | 6 (4–13) | 0.973 | 34 | 70 |
| Albuminuria | 0.697 | 34 | 70 | |||
| Normoalbuminuria (< 30 mg/g) | 1321 (89) | 654 (89) | 667 (89) | ||
| Microalbuminuria (30–300 mg/g) | 129 (9) | 66 (9) | 63 (8) | ||
| Macroalbuminuria (> 300 mg/g) | 37 (2) | 16 (2) | 21 (3) | ||
| Thyrotropin (TSH), × 10–3 IU/l | 1.7 (1.2–2.4) | 1.6 (1.1–2.4) | 1.7 (1.2–2.4) | 0.892 | 34 | 53 |
| Diabetes duration | < 0.001 | 0 | 0 | |||
| 0–24 years | 893 (56) | 352 (46) | 541 (66) | ||
| ≥ 25 years | 698 (44) | 418 (54) | 280 (34) | ||
| Acute diabetes complications, 1- and 5-year history | |||||
| Severe hypoglycaemia, 1 year | 29 (2) | 13 (2) | 16 (2) | 0.698 | 0 | 0 |
| Severe hypoglycaemia, 5 years | 108 (7) | 46 (6) | 62 (8) | 0.211 | 0 | 0 |
| Diabetic ketoacidosis, 1 year | 30 (2) | 5 (1) | 25 (3) | < 0.001 | 0 | 0 |
| Diabetic ketoacidosis, 5 years | 108 (7) | 28 (4) | 80 (10) | < 0.001 | 0 | 0 |
| Microvascular complications 5-year history | |||||
| Retinopathy (any) | 155 (10) | 84 (11) | 71 (9) | 0.129 | 0 | 0 |
| Neuropathy | 266 (17) | 146 (19) | 120 (15) | 0.020 | 0 | 0 |
| Nephropathy | 173 (11) | 91 (12) | 82 (10) | 0.241 | 0 | 0 |
| Macrovascular/other complications 5-year history | |||||
| Cardiovascular disease | 316 (20) | 190 (25) | 126 (15) | < 0.001 | 0 | 0 |
| Cerebrovascular disease | 39 (2) | 17 (2) | 22 (3) | 0.548 | 0 | 0 |
| Atherosclerosis | 20 (1) | 12 (2) | 8 (1) | 0.296 | 0 | 0 |
| Chronic kidney disease | 24 (2) | 12 (2) | 12 (1) | 0.874 | 0 | 0 |
| Diabetic foot ulcer | 26 (2) | 16 (2) | 10 (1) | 0.176 | 0 | 0 |
| Amputation of feet or legs | 11 (1) | 8 (1) | 3 (0) | 0.105 | 0 | 0 |
| Charlson comorbidity index, mean (SD) | 0.7 (0.8) | 0.8 (0.8) | 0.6 (0.9) | 0.001 | 0 | 0 |
| Psychiatric illness 5-year history | |||||
| Depression | 41 (3) | 15 (2) | 26 (3) | 0.125 | 0 | 0 |
| Anxiety | 15 (1) | 5 (1) | 10 (1) | 0.241 | 0 | 0 |
Descriptive statistics for categorical data are given as frequencies (%, without missing values) and for continuous data as medians (25th–75th percentiles). Cardiovascular disease includes (1) ischaemic heart disease, (2) heart failure, (3) hypertensive disease and (4) atrial fibrillation/flutter. Cerebrovascular disease includes (1) stroke (ischaemic and haemorrhagic) and (2) transient ischaemic attack. Chronic kidney disease (CKD) includes (1) moderate CKD, (2) severe CKD and (3) end-stage CKD (including dialysis and kidney transplant). *P values are for bivariate association tests. Figure 4 depicts adjusted multivariate analysis results
Device characteristics of responders (n = 770)
| Variables | Descriptive statistics ( | Missing |
|---|---|---|
| Insulin pump duration, years | 9 (6–13) | 11 |
| Age at insulin pump start, years | 39 (27–49) | 12 |
| Insulin pump type | 9 | |
| Insulin pump with tubing | 586 (77) | |
| Insulin patch pump | 175 (23) | |
| Glucose monitor type | 23 | |
| BGMa | 170 (23) | |
| isCGMb | 204 (27) | |
| CGMc | 373 (50) | |
| Sensor duration, years | 4 (2–7) | |
| Age at sensor start, years | 45 (31–55) | 1 |
| Insulin delivery system | 23 | |
| Insulin pump + BGM | 170 (23) | |
| Insulin pump + CGM/isCGM/SAPd | 268 (36) | |
| Insulin pump + LGSe/PLGSf | 247 (33) | |
| Insulin pump + HCLg/DIYh | 62 (8) |
Descriptive statistics for categorical data are given as frequencies (%, without missing values) and for continuous data as median (p25–p75) or mean (standard deviation)
aBlood glucose monitor
bIntermittently scanned continuous glucose monitor
cContinuous glucose monitor
dSensor-augmented insulin pump
eLow glucose suspend
fPredictive low-glucose suspend
gHybrid closed loop
hDo-it-yourself closed-loop systems
Fig. 2Response rate distribution by age group. Dashed line indicates the overall response rate (48.4%)
Fig. 3HbA1c distribution by age group of responders versus non-responders. Dashed line indicates recommended target HbA1c level (53 mmol/mol; 7.0%)
|
|
| •Insulin pump therapy can improve quality of life and glycaemic control for many people with type 1 diabetes; however, heterogeneity in outcomes persist, and little is known about reasons for this. |
| •Analysis of the Steno Tech data may inform interventions aimed at improving outcomes of insulin pump treatment taking differences between responders and non-responders into account. |
|
|
| •The Steno Tech Survey cohort of insulin pump users with type 1 diabetes was established using real-world clinical outcomes data from national registries and an elaborate questionnaire-based survey to assess insulin pump practices and psychosocial health. |
| •Questionnaire responders were older and had lower Hba1c compared with non-responders, but did not differ regarding annual income, diabetes duration, long-term diabetes complications and other comorbidities. |
| •This study may serve as an example of how to assess non-response bias and posits that future studies should focus especially on reaching young people and those facing challenges in meeting glycaemic targets. |